EUROPEAN CURRICULUM VITAE FORMAT

PERSONAL INFORMATION



Name	**TZVEOVA, RENI STOYOVA**
Address	**59, MITROPOLIT AVKSENTII VELESHKI STR., 1220, Nadejda 2, Sofia, Bulgaria**
Telephone	**+359 886 18 25 11**
Fax	
E-mail	renitzveova@abv.bg
Nationality	Bulgarian
Date of birth	06.10.1981

WORK EXPERIENCE

• Dates (from – to)	12.2024 - current
• Name of employer	Institute of Experimental Morphology, Pathology and Anthropology with Museum IEMPAM- BAS
• Occupation or position held	Assistant professor
• Dates (from – to)	06.2020-12.2024
• Name of employer	University Multidisciplinary Hospital for Active Treatment "Tsaritsa Joanna - ISUL"
• Type of business or sector	analytical, diagnostic
• Occupation or position held	Molecular biologist
• Main activities and responsibilities	Molecular – genetic diagnostics in patients with various oncological diseases (melanoma, colorectal carcinoma, thyroid tumors and others) in connection with referral to appropriate and effective targeted therapy. Mutational status analysis of *BRAF, KRAS, NRAS, PIK3CA, EGFR* and other genes with real-time polymerase chain reaction and digital PCR system.
• Dates (from – to)	2019-2020
• Name and address of employer	National center of public health and analyzes, Ministry of Health, 15 Acad. I. E. Geshov bul. Sofia, Bulgaria
• Type of business or sector	Research, analytical, expert
• Occupation or position held	assistant
• Main activities and responsibilities	DNA isolation, molecular - genetic analysis of DNA samples

• Dates (from – to)	2017-2018
• Name and address of employer	Executive Environment Agency, Ministry of Environment and Water, 136, Tsar Boris III Blvd., Sofia
• Type of business or sector	expert
• Occupation or position held	Chief Expert
• Main activities and responsibilities	DNA isolation, molecular - genetic analysis of plant samples

• Dates (from – to)	2014-2017
• Name and address of employer	Molecular Medicine Center, Medical University – Sofia, 2 Zdrave str. 1431 Sofia, Bulgaria
• Type of business or sector	Molecular biology and genetics
• Occupation or position held	Biologist - geneticist
• Main activities and responsibilities	DNA isolation, SNP genotyping, Next Generation sequencing, Sanger sequencing, Data anlysis

EDUCATION AND TRAINING

• Dates (from – to)	2011-2015
• Name and type of organization providing education and training	Medical University of Sofia
• Principal subjects/occupational skills covered	Pharmacogenetic studies in cardiovascular diseases
• Title of qualification awarded	PhD in Molecular genetics
• Level in national classification (if appropriate)	

• Dates (from – to)	2010-2012
• Name and type of organization providing education and training	Sofia University “St. Kliment Ochridski”
• Principal subjects/occupational skills covered	Drug chemistry, drug technology, pharmacology
• Title of qualification awarded	Master degree in Medical chemistry
• Level in national classification (if appropriate)	

• Dates (from – to)	2008-2010
• Name and type of organization providing education and training	Sofia University “St. Kliment Ochridski”
• Principal subjects/occupational skills covered	Molecular genetics, oncogenetics, genetic engineering
• Title of qualification awarded	Master degree in Genetics
• Level in national classification (if appropriate)	

• Dates (from – to)	1999-2006
• Name and type of organization providing education and training	Sofia University “St. Kliment Ochridski”
• Principal subjects/occupational skills covered	Molecular biology, molecular genetics
• Title of qualification awarded	Bachelor degree in Molecular biology
• Level in national classification (if appropriate)	

PERSONAL SKILLS AND COMPETENCES

Acquired in the course of life and career but not necessarily covered by formal certificates and diplomas.

MOTHER TONGUE

BULGARIAN

OTHER LANGUAGES

ENGLISH

- Reading skills: EXCELLENT
- Writing skills: GOOD
- Verbal skills: GOOD

SOCIAL SKILLS AND COMPETENCES

Living and working with other people, in multicultural environments, in positions where communication is important and situations where teamwork is essential (for example culture and sports), etc.

COMMUNICATION, TEAMWORK, TOLERANCE, LOYALTY

ORGANISATIONAL SKILLS AND COMPETENCES

Coordination and administration of people, projects and budgets; at work, in voluntary work (for example culture and sports) and at home, etc.

ORGANIZATION, RESPONSIBILITY, PRECISENESS

TECHNICAL SKILLS AND COMPETENCES

With computers, specific kinds of equipment, machinery, etc.

WORK AT COMPUTER, WORK AT NEXT GENERATION SEQUENCER MISEQ (ILLUMINA)

ARTISTIC SKILLS AND COMPETENCES

Music, writing, design, etc.

[Describe these competences and indicate where they were acquired.]

OTHER SKILLS AND COMPETENCES

Competences not mentioned above.

- extraction and purification of nucleic acids from different biological samples
- the full range of electrophoretic techniques
- diagnostic and scanning techniques for mutation detection
- sequencing, analysis of DNA polymorphism, including RFLPs
- PCR

DRIVING LICENCE(S)

Category B

ADDITIONAL INFORMATION

Research interest in:

- Inherited disorders and predisposition
- Pharmacogenomics
- Regulation of gene expression
- Neurodegenerative disorders
- Medical chemistry
- Pharmacoeconomics

ANNEXES [List any attached annexes.]

LIST OF PUBLICATIONS:

In foreign journals with an impact factor:

1. Yaneva-Sirakova, Teodora; Dodova, Rumiana; Kaneva, Radka; **Tzveova, Ren**i; Ivanova, Raya; Vassilev, Dobrin. A STUDY OF SOME GENETIC FACTORS FOR FIBROMUSCULAR DYSPLASIA. Journal of Hypertension: June 2022 - Volume 40 - Issue Suppl 1 - p e220-e221 doi: 10.1097/01.hjh.0000837712.75398.19
2. Penchev V, Boueva A, Kamenarova K, Roussinov D, **Tzveova R**, Ivanova M, Dimitrova V, Kremensky I, Mitev V, Kaneva R, Beltcheva O. A familial case of severe infantile nephronophthisis explained by oligogenic inheritance. Eur J Med Genet. 2017 Jun;60(6):321-325.
3. Kamenarova K, Simeonov E, **Tzveova R**, Dacheva D, Penkov M, Kremensky I, Perenovska P, Mitev V, Kaneva R. Identification of a novel de novo mutation of CREBBP in a patient with Rubinstein-Taybi syndrome by targeted next-generation sequencing: a case report. Hum Pathol. 2016 Jan;47(1):144-9.
4. Beltcheva O, Boueva A, **Tzveova R**, Roussinov D, Marinova S, Kaneva R, Mitev V. Steroid-resistant nephrotic syndrome caused by novel WT1 mutation inherited from a mosaic parent. Ren Fail. 2015 Dec 1:1-4.
5. **Tzveova R**., Naydenova G., Yaneva T., Dimitrov G., Vandeva S., Matrozova Y., Pendicheva-Duhlenska D., Popov I., Beltheva O., Naydenov C., Tarnovska-Kadreva R., Nachev G., Mitev V., Kaneva R. Gender specific effect of *CYP2C8*3* on the risk of essential hypertension in Bulgarian patients. *Biochem Genet. 2015 Dec;53(11-12):319-33.* IF 0.99.
6. Dimitrova-Karamfilova A., **Tzveova R**., Chilingirova N., Goranova T., Nachev G., Mitev V., Kaneva R. Acenocoumarol pharmacogenetic dosing algorithms and their application in two Bulgarian patients with extremely low anticoagulant requirements. *Biochem Genet. 2015 Dec;53(11-12):334-50.* IF 0.99.
7. **Tzveova R**., Dimitrova-Karamfilova A., Saraeva R., Solarova T., Naydenova G., Petrova I., Hristova N., Popov I., Nachev G., Mitev V., Kaneva K.. Estimation and validation of acenocoumarol dosing algorithms in Bulgarian patients with cardiovascular diseases. *Personalized medicine, 12(3), 211–222.* IF 1.13.

In specialized Bulgarian journals:

1. Ovcharova E, Danovska M, Marinova D, Pendicheva-Duhlenska D, Tonchev P, Atanasova M, Ruseva A, Shepherd N, **Tzveova R**. Adapted Mediterranean Diet Impact on the Symptoms of Chronic Fatigue, Serum Levels of Omega-3 Polyunsaturated Fatty Acids (PUFAs) and Interleukin 17 (IL-17) in Patients with Relapsing-Remitting Multiple Sclerosis undergoing Disease-Modifying Therapy: A Pilot Study. J of IMAB. 2022 Jan-Mar;28(1):4297-4304. DOI: 10.5272/jimab.2022281.4297
2. Yaneva-Sirakova T, Dodova R, Kaneva R, **Tsveova R**, Ivanova R, Vasilev D. Screening for fibromuscular dysplasia in Bulgarian patients and genetic aspects. Cardiovascular Diseases, Cardiovascular diseases. 2021, 52, № 2, 29-38.
3. Yordanov S., **Tzveova R.**, Goranova T., Pierini S., Genadieva M., Konov D., Popov T., Kaneva R., Rangachev Y. **"**Molecular Basis of Laryngeal Carcinogenesis and the Role of Promoter Hypermethylation", International Bulletin of Otorhinolaryngology. 2020; Volume 11: 28-36.
4. **Tzveova R**., Naydenova G., Yaneva T., S. Vandeva S., Pendicheva-Duhlenska D., Atanasov P., Beltcheva O., Naydenov C., Mitev V., Kaneva R., Georgieva T. „Polymorphic variants in ADIPOQ gene and coronary artery disease risk in Bulgarian population". Cardiovascular diseases. 2019; 3: 11-25.
5. **Tzveova R**., Georgieva Ts. „Application of CRISPR/CAS9 gene editing technology in the treatment of cardiovascular diseases". Cardiovascular diseases. 2019; 3: 26-32.
6. Yaneva-Sirakova T, **Tzveova R**, Kaneva R, et al. The clinical point of view on whether polymorphic variants of CYP17A1 and PLEKHA7 genes can have a role in the development of coronary heart disease. Cardiovascular diseases. 2018; 1: 3-7.
7. **Tzveova R**., Dimitrova – Karamfilova A., Saraeva R., Beltcheva O., Nachev G., Mitev V., Kaneva R. Pharmacogenetics of drug response in Acenocoumarol and warfarin treatment. Cardiovascular diseases, 03/2016, XLVII, p. 29-48.

8. **Tzveova R.**, Yaneva T., Dimitrov G., Pendicheva-Duhlenska D., Vandeva S., Matrozova Y., Beltcheva O., Mitkova A., Naydenov C., Zacharieva S., Tarnovska-Kadreva R., Nachev G., Mitev V., Kaneva R. Locus 9P21 and the revolution in cardiovascular genetics – contribution in vascular pathology and evaluation of coronary artery disease risk. Cardiovascular diseases 01/2015, XLIV, p.31-40.
9. **Tzveova R.**, Yaneva T., Dimitrov G., Naydenov K., Tarnovska – Kadreva R., Kaneva R., Nachev G., Mitev V. The role of genome-wide association studies for understanding the genetic basis of arterial hypertension – part 2. Cardiovascular diseases, 03/2014, XLIV, p. 30-8.
10. **Tzveova R**., Vandeva S., Matrozova Y., Naydenova G., Pendicheva – Duhlenska D., Mitkova A., Zacharieva S., Nachev G., Mitev V., Kaneva R. Polymorphic variants in leading candidate-genes from genome-wide association studies and coronary artery disease risk – part two. Cardiovascular diseases, 02/2014, XLV, p. 48-57.
11. Naydenova G, **Tzveova R**, Nachev G, Mitev V, Kaneva R. The effect of polymorphisms in *PCSK 9* gene on cholesterol levels and the risk of coronary artery disease. Cardiovascular diseases, 01/2014, XLV, p. 28-36.
12. Paskaleva I, Dineva D, Baycheva V, **Tzveova R**, Kaneva R, Georgiev B, Gocheva N. The influence of genetic variants *CYP2C19*2* and *CYP2C19*17* on ADP – induced platelet aggregation in patients on thienopyridine treatment. Bulgarian cardiology, XIX, № 4, 2013, p. 16-26.
13. **Tzveova R.**, Yaneva T., Dimitrov G., Naydenov K., Tarnovska – Kadreva R., Kaneva R., Nachev G., Mitev V. The role of genome-wide association studies for understanding the genetic basis of arterial hypertension. Cardiovascular diseases, 03/2013, XLIV, p. 47-54.
14. **Tzveova, R.,** Mitkova A., Kaneva R., Nachev G., Mitev V. The role of genome-wide association studies for understanding the genetic basis of coronary artery disease. Cardiovascular diseases, 03/2013, XLIV, p. 55-64.
15. **Tzveova R.**, Mitkova A., Paskaleva I., Kaneva R., Mitev V.. The role of genetic factors in determining the clinical efficacy of clopidogrel. Cardiovascular diseases, XLIV, № 1, 2013, p. 16-29.
16. **Tzveova, R**., Naydenova G., Kaneva R, Tzekova M., Nachev, G., Mitev, V. Role of genetic *polymorphisms in plasminogen activator inhibitor type 1 (PAI-1) and apolipoprotein E (ApoE) genes* in development of acute myocardial infarction. Bulgarian cardiology, **XVIII**, № 4, 2012, p. 36-42.
17. Naydenova G, **Tzveova R**, Kaneva R, Tzekova M. Genetic polymorphisms in *CYP2C8*, *CYP2C9*, *CYP2J2* and risk of coronary artery disease. Medinfo, 04/2012, Year XII, 4/2012, page 38-41